Close Menu
    Daten

    [OC] Die teuersten Einzeldosis-Medikamente der Welt im Vergleich zu den lebenslangen Kosten für die Behandlung derselben Erkrankung ohne sie


    [OC] Die teuersten Einzeldosis-Medikamente der Welt im Vergleich zu den lebenslangen Kosten für die Behandlung derselben Erkrankung ohne sie

    Von No_Turnover8182

    View 2 Comments

    2 Kommentare

    1. No_Turnover8182 on

      Prices are US wholesale acquisition cost (WAC) from FDA approval announcements and manufacturer press releases. Net prices after rebates are typically 20-25% lower. Lifetime costs from peer-reviewed literature:

      * Hemophilia B lifetime: $20-23M, midpoint $21.5M used in chart (PubMed PMID 33591884, adult payer perspective)
      * SMA/Spinraza: $750K first year, $375K/yr ongoing. $4.7M figure reflects ~11 years of treatment (BMC Cost Effectiveness and Resource Allocation, 2020)
      * Sickle cell: $1.6-4.2M depending on severity (Blood Advances, ASH 2022)

      Lifetime comparison bars only shown where solid peer-reviewed data exists. For Lenmeldy (MLD) and Elevidys (Duchenne), I couldn’t find reliable lifetime cost estimates in the literature, so those only show the gene therapy price.

      Tool: HTML/CSS, screenshotted at 3x

    2. Meet-me-behind-bins on

      I’ve read that there’s still a bit of an issue with the uptake and prescription of a lot of these drugs. It seems the economic argument is undeniable and yet they’re not being widely rolled out? I wonder if there’s lobbying and public relations campaigns from pharmaceutical companies that produce prophylaxis treatments that are wildly profitable? I get the district feeling that the last thing a lot of pharmaceutical companies want is to cure diseases. Why have a $4 million one off when you can have a $25 million lifetime customer?

    Leave A Reply